Brokerages expect Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) to post sales of $23.15 million for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for Deciphera Pharmaceuticals’ earnings. The highest sales estimate is $25.00 million and the lowest is $21.29 million. Deciphera Pharmaceuticals posted sales of $15.45 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 49.8%. The business is scheduled to issue its next quarterly earnings report on Thursday, November 4th.
According to Zacks, analysts expect that Deciphera Pharmaceuticals will report full-year sales of $94.49 million for the current financial year, with estimates ranging from $85.52 million to $100.05 million. For the next financial year, analysts expect that the company will report sales of $205.52 million, with estimates ranging from $130.58 million to $258.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Deciphera Pharmaceuticals.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings results on Tuesday, August 3rd. The company reported ($1.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.06). Deciphera Pharmaceuticals had a negative net margin of 308.58% and a negative return on equity of 50.07%. The company had revenue of $23.57 million during the quarter, compared to the consensus estimate of $22.25 million.
Institutional investors and hedge funds have recently made changes to their positions in the company. Lazard Asset Management LLC bought a new position in shares of Deciphera Pharmaceuticals in the 1st quarter valued at $45,000. Eaton Vance Management bought a new position in shares of Deciphera Pharmaceuticals in the 1st quarter valued at $79,000. Macquarie Group Ltd. lifted its stake in shares of Deciphera Pharmaceuticals by 90.8% in the 2nd quarter. Macquarie Group Ltd. now owns 2,005 shares of the company’s stock valued at $73,000 after acquiring an additional 954 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Deciphera Pharmaceuticals by 8,556.0% in the 1st quarter. Royal Bank of Canada now owns 2,164 shares of the company’s stock valued at $97,000 after acquiring an additional 2,139 shares during the last quarter. Finally, E Fund Management Co. Ltd. bought a new position in shares of Deciphera Pharmaceuticals in the 1st quarter valued at $144,000. Institutional investors own 73.67% of the company’s stock.
NASDAQ DCPH traded up $1.23 on Monday, hitting $32.98. 762,440 shares of the company’s stock were exchanged, compared to its average volume of 372,105. The stock has a 50-day moving average of $31.26 and a 200-day moving average of $36.67. Deciphera Pharmaceuticals has a 52 week low of $26.20 and a 52 week high of $68.40. The stock has a market cap of $1.91 billion, a price-to-earnings ratio of -7.33 and a beta of 1.50.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors.
Featured Article: Learning About the VIX – Volatility Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.